Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

KATIE Price’s 28 stone son faces more surgery after going on Ozempic jabs. And Harvey’s terrified mum fears the 22-year-old may die of a heart attack without help. Coming soon: Katie ...

KATIE Price’s 28 stone son faces more surgery after going on Ozempic jabs. And Harvey’s terrified mum fears the 22-year-old may die of a heart attack without help. Coming soon: Katie ...

It looks like VK2735 from Viking could compete fiercely with Eli Lilly's tirzepatide ... Lilly's next-generation anti-obesity candidate is called retatrutide, and it acts on GLP-1, GIP, and ...

It also reported preliminary data with an oral triple agonist called retatrutide – targeting GLP-1, GIP, and glucagon – that is also being advanced quickly into phase 3. Shares in Pfizer fell ...

Like Novo Nordisk's already-approved GLP-1 agonist Wegovy (semaglutide) and Lilly's dual GIP/GLP-1 agonist Mounjaro (tirzepatide ... GIP and glucagon known as retatrutide that is also being ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

If you continue to have this issue please contact [email protected]. Adults receiving tirzepatide in the SURPASS trials had significant decreases in urine albumin-to-creatinine ratio.

Novo Nordisk's semaglutide sales are enormous, but it's losing ground to tirzepatide, a more recently launched drug from Eli Lilly (NYSE: LLY) that acts on GLP-1 and GIP receptors. The dual ...

Eli Lilly's late-stage pipeline features such products as retatrutide, a potential novel weight loss treatment. Eli Lilly broke new ground with Zepbound. It's a dual GLP-1/GIP agonist, meaning it ...